Mark Lim

Dr. Mark Lim (Ph.D.) is the Executive Vice President and Chief Scientific Officer at AmberGen Inc. He has over 23 years’ experience in the biotechnology industry and has been awarded over 15 patents which underlie key technologies in the biotechnology industry, including in the fields of proteomics, genomics/transcriptomics and diagnostics. His early work at AmberGen on photocleavable linkers and protein engineering contributed to the commercialization of a variety of novel reagents including PC-Biotin, PC-Phosphoramidites and fluorescent suppressor tRNAs. These reagents currently underlie several commercialized techniques widely used in the proteomics/transcriptomics fields. Dr. Lim now leads the application of these core AmberGen technologies to multiomic biomarker discovery and biomarker-driven diagnostics. Dr. Lim co-invented AmberGen's PC-PURE technology for photo-affinity biomarker enrichment and in one example, used it to develop a multiplex, low blood-volume allergy immunodiagnostic in collaboration with Boston Children’s Hospital [Lim et al. (2018) https://doi.org/10.1371/journal.pone.0191987]. In a partnership with INOVA Diagnostics and MGH, he also spearheaded AmberGen’s R&D effort which led to the discovery of two novel autoantigen biomarkers for the autoimmune liver disease primary biliary cirrhosis, with the diagnostic assays currently undergoing FDA-clearance and CE Mark [Norman et al. (2015) https://doi.org/10.1111/liv.12690]. Most recently, he led the development of a new method for spatial multiomics and tissue diagnostics termed MALDI HiPLEX-IHC, which provides unprecedented targeted, top-town mass spectrometric imaging of macromolecular targets in cells and tissues using photocleavably mass-tagged probes [Yagnik et al. (2021) https://pubs.acs.org/doi/10.1021/jasms.0c00473].